ACHP Comments on Senate Finance Drug Pricing RFI
ACHP urges the Senate Finance Committee to lower drug prices at their source through PBM reform, biosimilar competition and Medicare negotiation.
ACHP urges the Senate Finance Committee to lower drug prices at their source through PBM reform, biosimilar competition and Medicare negotiation.
ACHP urges CMS to publish negotiation-eligible drug lists earlier and preserve Part D formulary flexibility for selected drugs under the IPAY 2029 rule.
ACHP urges CMS to advance PBM transparency under Section 6224 while protecting nonprofit, provider-aligned health plans from being treated as third-party PBMs.
ACHP letter backing H.R. 5526/S. 1954, which would eliminate the separate interchangeability designation for FDA-approved biosimilars, reducing costs and expanding patient access to lower-priced biologic therapies.
